No­vo Nordisk oral semaglu­tide tri­al shows re­duc­tion in blood sug­ar, plus weight loss

No­vo Nordisk is test­ing high­er lev­els of its oral ver­sion of its GLP-1, semaglu­tide, and its type 2 di­a­betes tri­al re­sults re­leased to­day show re­duc­tions in blood sug­ar as well as weight loss.

In the Phase II­Ib tri­al, No­vo com­pared its oral semaglu­tide in 25 mg and 50 mg dos­es with the 14 mg ver­sion that’s cur­rent­ly the max­i­mum ap­proved dose. The tri­al looked at how the dos­es com­pared when added to a sta­ble dose of one to three oral an­tidi­a­bet­ic med­i­cines in peo­ple with type 2 di­a­betes who were in need of an in­ten­si­fied treat­ment.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN